Antibody-Free Immunopeptide Nano-Conjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme

Area of Science:

• Nanomedicine
• Immunotherapy
• Neuro-oncology

Background:

• Glioblastoma Multiforme (GBM) is a deadly brain cancer with poor treatment outcomes.
• The blood-brain barrier (BBB) severely restricts therapeutic access to brain tumors.
• Current immunotherapies have limited efficacy against CNS tumors due to the BBB.

Purpose of the Study:

• To develop and evaluate an actively targeted nanoconjugate (P12/AP-2/NCs) for penetrating the BBB.
• To assess the immunotherapeutic potential of P12/AP-2/NCs in glioblastoma models.
• To investigate the mechanism of BBB traversal and immune modulation by the nanoconjugate.

Main Methods:

• Synthesis of P12/AP-2/NCs using biodegradable poly(L-malic acid) conjugated with PD-1/PD-L1 antagonist peptide (P12) and Angiopep-2 (AP2).
• In vitro evaluation of BBB permeability using a Transwell spheroid model.
• Assessment of T cell cytotoxicity and immune modulation in U87 GBM 3D spheroid models.
• In vivo biodistribution and safety studies in murine models.

Main Results:

• P12/AP-2/NCs successfully crossed an in vitro BBB model and were internalized into brain tumor spheroids.
• The nanoconjugate demonstrated significant T cell-mediated cytotoxicity against U87 GBM 3D spheroids.
• In vivo studies showed enhanced brain accumulation and prolonged bioavailability of P12/AP-2/NCs.
• Histopathology confirmed a favorable safety profile for the nanoconjugate at tested doses.

Conclusions:

• P12/AP-2/NCs represent a novel nanoconjugate platform capable of BBB penetration.
• The nanoconjugate effectively modulates the tumor immune microenvironment and enhances anti-tumor activity.
• This approach offers a promising strategy for treating glioblastoma and other CNS malignancies without antibodies.